PDE-5 inhibitors increase risk of biochemical recurrence after radical prostatectomy
the ONA take:
According to a new study published in The Journal of Urology, researchers have found that taking phosphodiesterase type 5 inhibitors following radical prostatectomy is associated with an elevated risk of biochemical recurrence.
Phosphodiesterase type 5 inhibitors include sildenafil, tadalafil, and vardenafil, and are indicated for the treatment of pulmonary hypertension and erectile dysfunction.
Researchers at University Hospital Hamburg-Eppendorf in Hamburg, Germany, sought to investigate the effect of phosphodiesterase type 5 inhibitors on biochemical recurrence following a radical prostatectomy in patients with prostate cancer.
Researchers analyzed data from nearly 5,000 patients with localized prostate cancer who underwent bilateral nerve-sparing radical prostatectomy. Of those, 23.4% used phosphodiesterase type 5 inhibitors following surgery.
During a median follow-up of 60.3 months, there was a 5-year biochemical recurrence-free survival of 84.7% in the phosphodiesterase type 5 inhibitor group compared with 89.2% in the nonphosphodiesterase type 5 inhibitor group. Multivariate analysis showed that phosphodiesterase type 5 inhibitor use was an independent risk factor for biochemical recurrence (HR = 1.38).
Taking phosphodiesterase type 5 inhibitors following radical prostatectomy is associated with an elevated risk of recurrence.
Sign Up for Free e-newsletters
- Education May Better Equip Nurses to Hold End-of-Life Conversations in Advanced Cancer
- Avoiding the ED: Planned Strategies for Unplanned Urgent Cancer Care
- NP-Led Clinics Improved Phase 1 Oncology Study Operations, Outcomes
- Accurate Understanding of Capacity May Improve Workflow, Efficiency in Infusion Suite
- Art as Palliative Care: Bedside Intervention Improves Pain, Anxiety, Mood in Hospitalized Cancer Patients
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|